CD44 as a prognostic marker in early colorectal cancer: single center experience “South Egypt cancer institute”, Egypt

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Howlader N. SEER cancer statistics review, 1975–2016. Natl Cancer Inst. 2019;1:85–88.
   Google Scholar
• Zheng W. Improving the overall survival prognosis prediction accuracy: A 9‐ gene signature in CRC patients. Cancer Med. 2021;10(17):5998–6009. doi: 10.1002/cam4.4104
   PubMed Web of Science ®Google Scholar
• Sawicki T, Ruszkowska M, Danielewicz A, et al. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers. 2021;13(9):2025. doi: 10.3390/cancers13092025
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Khaled, H.M., Mikhail, N.N. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014. doi:10.1155/2014/437971.
   PubMedGoogle Scholar
• Sharma R, Aashima NM, Fronterre C, et al. Mapping Cancer in Africa: A comprehensive and comparable characterization of 34 cancer types using estimates from glOBOCAN 2020. Front Public Health. 2022 Apr 25;10:839835.
   PubMed Web of Science ®Google Scholar
• Holah NS, Aiad H, Asaad N, et al. Evaluation of the role of CD44 as a cancer stem cell marker in colorectal carcinoma: Immunohistochemical study. Menoufia Med J. 2017;30(1):174. doi: 10.4103/mmj.mmj_151_16
   Google Scholar
• Kassem AM, El-Guendy N, Tantawy M, et al. Mutational hotspots in the mitochondrial D- loop region of cancerous and precancerous colorectal lesions in Egyptian patients. DNA Cell Biol. 2011;30(11):899–906. doi: 10.1089/dna.2010.1186
   PubMed Web of Science ®Google Scholar
• Islam F,Gopalan, V., Smith, R.A. Translational potential of cancer stem cells: A review of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment. Exp Cell Res. 2015;335(1):135–. doi: 10.1016/j.yexcr.2015.04.018
   PubMed Web of Science ®Google Scholar
• Hatano Y, Fukuda S, Hisamatsu K, et al. Multifaceted interpretation of colon cancer stem cells. Int J Mol Sci. 2017;18(7):1446. doi: 10.3390/ijms18071446
   PubMed Web of Science ®Google Scholar
• Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11(4):254–267. doi: 10.1038/nrc3023
   PubMed Web of Science ®Google Scholar
• Hassn Mesrati M, Syafruddin SE, Mohtar MA, et al. CD44: A multifunctional mediator of cancer progression. Biomolecules. 2021;11(12):1850. doi: 10.3390/biom11121850
   PubMed Web of Science ®Google Scholar
• He Y, Xue C, Yu Y, et al. CD44 is overexpressed and correlated with tumor progression in gallbladder cancer. Cancer Manage Res. 2018;10:3857–3865. DOI:10.2147/CMAR.S175681
   PubMed Web of Science ®Google Scholar
• Hurt EM. CD44+ CD24− prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 2008;98(4):756–765.
   PubMed Web of Science ®Google Scholar
• Wang Z, Tang Y, Xie L. The prognostic and clinical value of CD44 in colorectal cancer: a meta-analysis. Front Oncol. 2019;9:309. DOI:10.3389/fonc.2019.00309
   PubMed Web of Science ®Google Scholar
• Nour El Hoda SI, Sharaf, W.M. Helmy, D.O. Detection of cancer stem cells in colorectal cancer: histopathological and immunohistochemical study. Open Access Maced J Med Sci. 2016;4(4):543. doi: 10.3889/oamjms.2016.126
   PubMedGoogle Scholar
• Liu D,Sun, J. Zhu, J. Expression and clinical significance of colorectal cancer stem cell marker EpCAM(high)/CD44(+) in colorectal cancer. Oncol Lett. 2014;7(5):1544–1548.
   PubMed Web of Science ®Google Scholar
• Bánky B, Rásó-Barnett L, Barbai T, et al. Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression. Mol Cancer. 2012;11(1):1–15. doi: 10.1186/1476-4598-11-83
   PubMedGoogle Scholar
• Lugli A, Iezzi G, Hostettler I, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer. 2010;103(3):382–390. doi: 10.1038/sj.bjc.6605762
   PubMed Web of Science ®Google Scholar
• Chun SY, Bae OS, Kim JB, et al. The significance of CD44 variants expression in colorectal cancer and its regional lymph nodes. J Korean Med Sci. 2000;15(6):696–700. doi: 10.3346/jkms.2000.15.6.696
   PubMed Web of Science ®Google Scholar
• Chen S,Song, X.M., Chen, Z.H. Correlation analysis of CD133/CD44 expression in colorectal cancer tissues and 5-year survival rate in colorectal cancer patients. Chin J Pathophysiol. 2011;27:883–889.
   Google Scholar
• Zhao L,Lin, Q.L, and Wei, J. Cd44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression. Int J Clin Exp Pathol. 2015;8(1) .
   Web of Science ®Google Scholar
• Li X-D, Ji M, Wu J, et al. Clinical significance of CD44 variants expression in colorectal cancer. Tumori J. 2013;99(1):88–92. doi: 10.1177/030089161309900115
   PubMed Web of Science ®Google Scholar
• Huh JW. Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int. 2009;59(4):241–. doi: 10.1111/j.1440-1827.2009.02357.x
   PubMed Web of Science ®Google Scholar
• Yan X, Han D, Chen Z, et al. RUNX2 interacts with BRG1 to target CD44 for promoting invasion and migration of colorectal cancer cells. Cancer Cell Int. 2020;20(1):1–13. doi: 10.1186/s12935-020-01544-w
   PubMed Web of Science ®Google Scholar
• Galizia G. Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. Arch Surg. 2012;147(1):18–24. doi: 10.1001/archsurg.2011.795
   PubMedGoogle Scholar
• El-Hennawy MM. Rectal carcinoma in Egyptian patients less than 40 years of age. Int Surg. 2003;88(3):137–144.
   PubMed Web of Science ®Google Scholar